Personal information

Other IDs

Scopus Author ID: 24778375400

Activities

Collapse all

Employment (2)

University of Alabama at Birmingham: Birmingham, AL, US

1995 to present | Professor (Neurology)
Employment
Source: Self-asserted source
Louis Nabors

US Navy: Jacksonville, FL, US

1991 to 1995 | Flight Surgeon (Medicine)
Employment
Source: Self-asserted source
Louis Nabors

Education and qualifications (2)

University of Tennessee Medical Center: Knoxville, TN, US

1986 to 1991 | MD (Medicine)
Education
Source: Self-asserted source
Louis Nabors

Mississippi State University: Mississippi State, MS, US

1981 to 1985 | BS (Biological Engineering)
Education
Source: Self-asserted source
Louis Nabors

Works (50 of 172)

Items per page:
Page 1 of 4

NCCN CNS Tumor Guidelines Update for 2024

Neuro-Oncology
2025-03-07 | Journal article
DOI: 10.1093/neuonc/noae267
Contributors: Louis Burt Nabors; Jona Hattangadi-Gluth; Craig Horbinski; Jana Portnow
Source: check_circle
Crossref

Data from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.c.7234922
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Data from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.c.7234922.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

Clinical Cancer Research
2024-05-15 | Journal article
DOI: 10.1158/1078-0432.CCR-23-3241
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826600.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826600
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826597.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826597
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826594
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826594.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Material 1 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826591.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Material 1 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826591
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Table S1 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826588
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Table S1 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826588.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Table S2 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826579
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Table S2 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826579.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Table S3 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826576
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Supplementary Table S3 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

2024-05-15 | Preprint
DOI: 10.1158/1078-0432.25826576.v1
Contributors: Karisa C. Schreck; Roy E. Strowd; Louis B. Nabors; Benjamin M. Ellingson; Michael Chang; Sze K. Tan; Zied Abdullaev; Rust Turakulov; Kenneth Aldape; Neeraja Danda et al.
Source: check_circle
Crossref

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

Neuro-Oncology Advances
2024-01-01 | Journal article
DOI: 10.1093/noajnl/vdae009
Contributors: Samuel A Goldlust; Louis B Nabors; Sigmund Hsu; Nimish Mohile; Paul J Duic; Tara Benkers; Samuel Singer; Mayank Rao; Lori Cappello; Sandra L Silberman et al.
Source: check_circle
Crossref

NCCN CNS tumor guidelines update for 2023

Neuro-Oncology
2023-12-08 | Journal article
DOI: 10.1093/neuonc/noad169
Contributors: Burt Nabors; Jana Portnow; Jona Hattangadi-Gluth; Craig Horbinski
Source: check_circle
Crossref

Data from <i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528224.v1
Contributors: Monika E. Hegi; Els Genbrugge; Thierry Gorlia; Roger Stupp; Mark R. Gilbert; Olivier L. Chinot; L. Burt Nabors; Greg Jones; Wim Van Criekinge; Josef Straub et al.
Source: check_circle
Crossref

Data from <i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528224
Contributors: Monika E. Hegi; Els Genbrugge; Thierry Gorlia; Roger Stupp; Mark R. Gilbert; Olivier L. Chinot; L. Burt Nabors; Greg Jones; Wim Van Criekinge; Josef Straub et al.
Source: check_circle
Crossref

Data from Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528608
Contributors: Jaishri O. Blakeley; Stuart A. Grossman; Andrew S. Chi; Tom Mikkelsen; Myrna R. Rosenfeld; Manmeet S. Ahluwalia; L. Burt Nabors; April Eichler; Ignacio Garcia Ribas; Serena Desideri et al.
Source: check_circle
Crossref

Data from Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528608.v1
Contributors: Jaishri O. Blakeley; Stuart A. Grossman; Andrew S. Chi; Tom Mikkelsen; Myrna R. Rosenfeld; Manmeet S. Ahluwalia; L. Burt Nabors; April Eichler; Ignacio Garcia Ribas; Serena Desideri et al.
Source: check_circle
Crossref

Data from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531057
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Data from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531057.v1
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Supplementary Data from <i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22472453
Contributors: Monika E. Hegi; Els Genbrugge; Thierry Gorlia; Roger Stupp; Mark R. Gilbert; Olivier L. Chinot; L. Burt Nabors; Greg Jones; Wim Van Criekinge; Josef Straub et al.
Source: check_circle
Crossref

Supplementary Data from <i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22472453.v1
Contributors: Monika E. Hegi; Els Genbrugge; Thierry Gorlia; Roger Stupp; Mark R. Gilbert; Olivier L. Chinot; L. Burt Nabors; Greg Jones; Wim Van Criekinge; Josef Straub et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483056
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Supplementary Figure 1 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483056.v1
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Supplementary Table 1 from Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473791
Contributors: Jaishri O. Blakeley; Stuart A. Grossman; Andrew S. Chi; Tom Mikkelsen; Myrna R. Rosenfeld; Manmeet S. Ahluwalia; L. Burt Nabors; April Eichler; Ignacio Garcia Ribas; Serena Desideri et al.
Source: check_circle
Crossref

Supplementary Table 1 from Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473791.v1
Contributors: Jaishri O. Blakeley; Stuart A. Grossman; Andrew S. Chi; Tom Mikkelsen; Myrna R. Rosenfeld; Manmeet S. Ahluwalia; L. Burt Nabors; April Eichler; Ignacio Garcia Ribas; Serena Desideri et al.
Source: check_circle
Crossref

Supplementary Table 1 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483053
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Supplementary Table 1 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483053.v1
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Supplementary Table 3 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483050
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Supplementary Table 3 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483050.v1
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Table 2 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483047
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Table 2 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483047.v1
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

The road we travel

Neuro-Oncology
2023-01-05 | Journal article
DOI: 10.1093/neuonc/noac235
Contributors: Burt Nabors
Source: check_circle
Crossref

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Clinical Cancer Research
2022-02-15 | Journal article
DOI: 10.1158/1078-0432.CCR-21-2750
Contributors: Stephen J. Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q. Lee; Gavin P. Dunn; Evanthia Galanis; Susan M. Chang; Louis Burt Nabors; Manmeet S. Ahluwalia; Roger Stupp et al.
Source: check_circle
Crossref

SRI‐42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide‐induced neuroinflammation

Glia
2022-01 | Journal article
DOI: 10.1002/glia.24094
Contributors: Rajeshwari Chellappan; Abhishek Guha; Ying Si; Thaddaeus Kwan; Louis B. Nabors; Natalia Filippova; Xiuhua Yang; Anish S. Myneni; Shriya Meesala; Ashley S. Harms et al.
Source: check_circle
Crossref

High-dose Methotrexate and Rituximab Induction Regimen In Immunocompetent Patients With Primary CNS Lymphoma: A Retrospective Single-Center Study of Survival Predictors

2022-01-14 | Preprint
DOI: 10.21203/rs.3.rs-1250355/v1
Contributors: Andrew Burton DeAtkine; Moaaz Abdelrashid; Zach Tucker; James M. Markert; Jinsuh Kim; John B. Fiveash; Robert A. Oster; Mina Lobbous; L. Burt Nabors
Source: check_circle
Crossref

Targeting the TREM1-positive myeloid microenvironment in glioblastoma

Neuro-Oncology Advances
2022-01-01 | Journal article
DOI: 10.1093/noajnl/vdac149
Contributors: Natalia Filippova; Jeffrey M Grimes; Jianmei W Leavenworth; David Namkoong; Xiuhua Yang; Peter H King; Michael Crowley; David K Crossman; L Burt Nabors
Source: check_circle
Crossref

Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

Clinical Cancer Research
2022-01-01 | Journal article
DOI: 10.1158/1078-0432.CCR-21-1987
Contributors: Julia Furtner; Michael Weller; Michael Weber; Thierry Gorlia; Burt Nabors; David A. Reardon; Joerg C. Tonn; Roger Stupp; Matthias Preusser
Source: check_circle
Crossref

Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations—An Exemplar in Brain Tumors

JCO Clinical Cancer Informatics
2021-12 | Journal article
DOI: 10.1200/CCI.21.00052
Contributors: Christine Woo; Gino N. Cioffi; Taissa A. Bej; Brigid Wilson; Janet M. Briggs; Sarah C. Markt; Fredrick R. Schumacher; Carol Kruchko; Kristin A. Waite; L. Burt Nabors et al.
Source: check_circle
Crossref

Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Cancer Research
2021-04-15 | Journal article
DOI: 10.1158/0008-5472.can-20-2858
Part of ISSN: 0008-5472
Part of ISSN: 1538-7445
Source: Self-asserted source
Louis Nabors

Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics

Neuro-Oncology
2020-12-18 | Journal article
DOI: 10.1093/neuonc/noaa242
Contributors: Kasey R Skinner; L Burt Nabors; C Ryan Miller
Source: check_circle
Crossref

A troublesome burden, the amplification of EGFR in glioblastoma!

Neuro-Oncology
2020-05-15 | Journal article
DOI: 10.1093/neuonc/noaa055
Contributors: Mina Lobbous; L Burt Nabors
Source: check_circle
Crossref

Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma

Scientific Reports
2019-07-26 | Journal article
DOI: 10.1038/s41598-019-47284-4
Contributors: Jordan H. Creed; Noah C. Peeri; Gabriella M. Anic; Reid C. Thompson; Jeffrey J. Olson; Renato V. LaRocca; Sajeel A. Chowdhary; John D. Brockman; Travis A. Gerke; Louis B. Nabors et al.
Source: check_circle
Crossref

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Clinical Cancer Research
2019-03-15 | Journal article
DOI: 10.1158/1078-0432.CCR-18-3181
Contributors: Monika E. Hegi; Els Genbrugge; Thierry Gorlia; Roger Stupp; Mark R. Gilbert; Olivier L. Chinot; L. Burt Nabors; Greg Jones; Wim Van Criekinge; Josef Straub et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 4

Peer review (24 reviews for 6 publications/grants)

Review activity for Cellular and molecular life sciences (1)
Review activity for Journal of the National Cancer Institute : (1)
Review activity for Neuro-oncology advances. (4)
Review activity for Neuro-oncology. (16)
Review activity for Neurosurgery. (1)
Review activity for Neurotherapeutics. (1)
How many people are using ORCID?